J. Stevens

Zidovudine plus interferon-α versus zidovudine alone in HIV‐infected symptomatic or asymptomatic persons with CD4+ cell counts > 150x106/l: results of the Zidon trial

C. Boucher, P. Dowd, J. Lang, 1995 .

Zidovudine plus interferon-alpha versus zidovudine alone in HIV-infected symptomatic or asymptomatic persons with CD4+ cell counts > 150 x 10(6)/L: results of the Zidon trial. Zidon Study Group.

C. Boucher, P. Dowd, J. Lang, 1995, AIDS.

Evaluation and clinical impact of a pharmacist-led, interdisciplinary service focusing on education, monitoring and toxicity management of immune checkpoint inhibitors

A. Flewelling, G. Myers, J. Stevens, 2021, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Urine test predicts kidney injury and death in COVID-19

V. D’Agati, R. Sampogna, K. Kiryluk, 2021, medRxiv.

Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.

Mark Stevenson, R. Rafia, D. Papaioannou, 2012, Health technology assessment.

Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter

J. Gatell, D. Cooper, F. Goebel, 1993 .